IQV

TentativeAI Memo

IQVIA

As of 2026-10-25/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

—

Confidence

medium

Horizon

—

Key catalyst

October 27 Q3 results test R&D bookings conversion and raised guidance • 2026-10-27

Base target: $302 / p=50% prob

Biggest risk

Bookings may convert more slowly than expected, margins or cash flow may disappoint, and the October product launches have no disclosed monetization. At June 30, IQVIA reported $14.09 billion net debt and 3.59x net leverage [#SEC-8K-2026-07-28]. A subsidiary also priced $2 billion of 2034 notes, but the supplied relationship evidence does not establish a net leverage change [#REL-484279c4-fca9-4ae4-bf4d-c8191a6631e4]. Sources: https://www.sec.gov/Archives/edgar/data/1478242/000162828026049923/iqv-q2x2026earningspressre.htm ; https://www.sec.gov/Archives/edgar/data/1478242/000119312526386633/d516985dex992.htm

Invalidation

Break below $240 or thesis failure.

What would change my mind?

The positive deterministic prior is supported by Q2 revenue growth of 8.7%, R&D Solutions bookings growth of 19%, 1.22x book-to-bill, and higher 2026 guidance. If Q3 confirms backlog conversion and continued commercial growth, the stock could approach the bull scenario. IQVIA's July release projected about $9.2 billion of R&D backlog converting over the next 12 months [#SEC-8K-2026-07-28]. Source: https://www.sec.gov/Archives/edgar/data/1478242/000162828026049923/iqv-q2x2026earningspressre.htm

Research note

Recommendation

—

Confidence

medium

As of

2026-10-25

Base target

$302

p=50%

Bull target

$330

p=25%

Bear target

$240

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Explorer paid commercial adoption
Life Science Models validation and monetization
The positive deterministic prior is supported by Q2 revenue growth of 8.7%, R&D Solutions bookings growth of 19%, 1.22x book-to-bill, and higher 2026 guidance.

BearKey bullets

Commercial Solutions relies on numerous third-party data suppliers; concentration and availability effects are undisclosed [#REL-c8fc4ab8-39dc-44ce-9255-96cd7fa29297].
Source: https://www.sec.gov/Archives/edgar/data/1478242/000162828026008322/iqv-20251231.htm
Explorer and Life Science Models have no disclosed incremental revenue or paid-adoption metrics [#IR-2026-10-07-EXPLORER] [#IR-2026-10-07-MODELS].

WatchKey bullets

October 27 Q3 results test R&D bookings conversion and raised guidance

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $302 (p=50%)

Target spread vs base: +9% / -21%

Scenario probabilities

Bull Target: $330 (p=25%)Base Target: $302 (p=50%)Bear Target: $240 (p=25%)

Commentary

Company-reported Q2 strength and the dated October 27 earnings event support a cautiously positive monitoring view, consistent with the deterministic positive prior. The October 22 Zacks item is a pre-earnings preview, not an IQVIA release; its $4.4 billion revenue and $3.24 EPS figures are third-party consensus estimates, not results. No verified post-launch price reaction, current target revisions, options, short-interest, employee or sufficient social measurements were supplied; sentiment zeros denote unavailable data, not observed neutrality. One required fresh relationship extraction failed, so absence of additional links is not evidence of absence.

As of 2026-10-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Explorer paid commercial adoption
Life Science Models validation and monetization

Scenarios

Bull Target (Scenario probability)

$330 / p=25% prob

Base Target (Scenario probability)

$302 / p=50% prob

Bear Target (Scenario probability)

$240 / p=25% prob

Analysis 2026-10-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-27
October 27 Q3 results test R&D bookings conversion and raised guidance
IQVIA scheduled Q3 results before the October 27 open. Q2 R&D Solutions bookings were $3.15 billion, book-to-bill was 1.22x, and contracted backlog was $34.2 billion; the July release raised 2026 revenue, adjusted EBITDA and adjusted EPS guidance. Watch bookings, backlog conversion, margins and cash flow rather than treating awards as immediate revenue: clinical-research services are generally delivered over time [#IR-2026-09-29] [#SEC-8K-2026-07-28] [#10-Q-2026-07-28] [#REL-2a644bd1-bf19-4a9e-a143-a9b08710188e]. Sources: https://ir.iqvia.com/press-releases/press-release-details/2026/IQVIA-to-Announce-Third-Quarter-2026-Results-on-October-27-2026/default.aspx ; https://www.sec.gov/Archives/edgar/data/1478242/000162828026049923/iqv-q2x2026earningspressre.htm ; https://www.sec.gov/Archives/edgar/data/1478242/000162828026008322/iqv-20251231.htm
Prob 100.00% • Move 5.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Explorer paid commercial adoption
2027-06-30
IQVIA introduced Explorer on October 7 as an always-on commercial intelligence offering. The company did not quantify paid uptake or incremental revenue; future disclosure of adoption and monetization is the test, not the launch itself [#IR-2026-10-07-EXPLORER]. Veeva identifies IQVIA as a competitor in Data Cloud and Crossix, but does not disclose the overlap's economics [#REL-db3cb69e-0940-46ca-95f0-6b61cc4a168f]. Sources: https://ir.iqvia.com/press-releases/press-release-details/2026/IQVIA-Launches-IQVIA-Explorer-to-Help-Life-Sciences-Companies-Make-Better-Commercial-Decisions/default.aspx ; https://www.sec.gov/Archives/edgar/data/1393052/000139305226000036/veev-20260731.htm
Prob 50% • Move 4% • Priced-in 35%
Life Science Models validation and monetization
2027-12-31
IQVIA introduced Life Science Models on October 7 for clinical-development prediction. The prior company-source baseline reports initial evaluations, but paid adoption and revenue remain undisclosed; validation in customer workflows is the substantive milestone [#IR-2026-10-07-MODELS]. Source: https://ir.iqvia.com/press-releases/press-release-details/2026/IQVIA-Launches-IQVIA-Life-Science-Models-to-Help-Life-Sciences-Companies-Predict-Clinical-Trial-Outcomes/default.aspx
Prob 45% • Move 4% • Priced-in 30%

Risks

Commercial Solutions relies on numerous third-party data suppliers; concentration and availability effects are undisclosed [#REL-c8fc4ab8-39dc-44ce-9255-96cd7fa29297]. Source: https://www.sec.gov/Archives/edgar/data/1478242/000162828026008322/iqv-20251231.htm
Explorer and Life Science Models have no disclosed incremental revenue or paid-adoption metrics [#IR-2026-10-07-EXPLORER] [#IR-2026-10-07-MODELS].
IQVIA says some services rely on third-party technology and IP licenses that could expire or terminate; affected revenue is unknown [#REL-1453584a-168f-432e-9a07-6045418b6e5d]. Source: https://www.sec.gov/Archives/edgar/data/1478242/000162828026008322/iqv-20251231.htm
June 30 net debt was $14.09 billion and net leverage was 3.59x; financing and cash-flow execution matter [#SEC-8K-2026-07-28].
October 27 results could show weaker R&D bookings, slower backlog conversion, or guidance pressure despite a strong Q2 [#SEC-8K-2026-07-28] [#REL-2a644bd1-bf19-4a9e-a143-a9b08710188e].

Peers

Symbol	Summary
FTRE	Direct CRO cross-check from the prior baseline, which records Q2 book-to-bill of 1.06x. Smaller scale and different mix limit valuation inference. Source: https://ir.fortrea.com/news-releases/news-release-details/fortrea-reports-second-quarter-2026-results
MEDP	Direct full-service CRO cross-check from the prior baseline, which records Q2 book-to-bill of 1.13x. Client mix and scale differ, so the comparison is directional. Source: https://investor.medpace.com/news-releases/news-release-details/medpace-holdings-inc-reports-second-quarter-2026-results
VEEV	Commercial-data and development-software competitor, not a whole-company CRO valuation peer. Veeva names IQVIA as a competitor in Data Cloud, Crossix, and certain Development and Quality Cloud applications; economic overlap is not disclosed [#REL-db3cb69e-0940-46ca-95f0-6b61cc4a168f] [#REL-1b1d1b54-4f9c-4053-ae1a-7cda678d19e6]. Source: https://www.sec.gov/Archives/edgar/data/1393052/000139305226000036/veev-20260731.htm
ICLR	Direct CRO operating cross-check. IQVIA identifies ICON among competitors [#REL-c84278e5-43f3-4521-967d-ea8043d23b21]. The prior baseline records ICON Q2 book-to-bill of 1.51x versus IQVIA's 1.22x R&D Solutions measure, but award definitions and business mix differ. Source: https://www.sec.gov/Archives/edgar/data/1478242/000162828026008322/iqv-20251231.htm

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-25

Loading AI feed…

Symbol

Summary

FTRE

Direct CRO cross-check from the prior baseline, which records Q2 book-to-bill of 1.06x. Smaller scale and different mix limit valuation inference. Source: https://ir.fortrea.com/news-releases/news-release-details/fortrea-reports-second-quarter-2026-results

MEDP

Direct full-service CRO cross-check from the prior baseline, which records Q2 book-to-bill of 1.13x. Client mix and scale differ, so the comparison is directional. Source: https://investor.medpace.com/news-releases/news-release-details/medpace-holdings-inc-reports-second-quarter-2026-results

VEEV

Commercial-data and development-software competitor, not a whole-company CRO valuation peer. Veeva names IQVIA as a competitor in Data Cloud, Crossix, and certain Development and Quality Cloud applications; economic overlap is not disclosed [#REL-db3cb69e-0940-46ca-95f0-6b61cc4a168f] [#REL-1b1d1b54-4f9c-4053-ae1a-7cda678d19e6]. Source: https://www.sec.gov/Archives/edgar/data/1393052/000139305226000036/veev-20260731.htm

ICLR

Direct CRO operating cross-check. IQVIA identifies ICON among competitors [#REL-c84278e5-43f3-4521-967d-ea8043d23b21]. The prior baseline records ICON Q2 book-to-bill of 1.51x versus IQVIA's 1.22x R&D Solutions measure, but award definitions and business mix differ. Source: https://www.sec.gov/Archives/edgar/data/1478242/000162828026008322/iqv-20251231.htm